March 5 - MODERNA (MRNA, Financial) secured a major legal win in its COVID-19 vaccine patent dispute with Pfizer (PFE, Financial) and BioNTech (BNTX, Financial). A Dusseldorf court ruled in favor of Moderna, according to a Wednesday court filing.
The court ruled that Pfizer and BioNTech must disclose any revenue gained from Moderna's patented technology, although the amount remains to be determined, and that they will pay extra.
Pfizer and BioNTech exercised legal authorization to use their patent until May 2023. The court made a decision that Moderna legally withdrew their consent in March 2022 so their previous patent permission became void. Legal analysts view the court decision as a major advancement within pharmaceutical intellectual property rights that affects the industry.
Industry stakeholders and investors now watch closely for further updates in this high-stakes patent conflict.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。